OptiNose (OPTN) shares were up more than 61% in premarket activity Thursday after the company overnight said it agreed to be acquired by Paratek Pharmaceuticals in a deal valued at up to $330 million.
The consideration payable to OptiNose shareholders is up to $14 per share, including contingent value rights tied to future commercial milestones, the companies said in a joint statement late Wednesday. It represents a 50% premium to Optinose's closing trading price on Wednesday.
The move will expand Paratek's commercial portfolio beyond its flagship antibiotic, nuzyra (omadacycline), and strengthen its focus on specialty therapies for primary care providers and specialists.
The acquisition includes OptiNose's approved product xhance (fluticasone propionate), a drug-device combination product approved to treat chronic rhinosinusitis. Paratek plans to "accelerate access for xhance beyond specialists to primary care providers maximizing the recent label expansion for CRS in a 10-million-patient market."
OptiNose also said late Wednesday it canceled its Q4 earnings conference call scheduled for March 20 following the announcement related to the takeover, which is subject to regulatory approvals.
Price: 9.71, Change: +3.71, Percent Change: +61.83
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。